Tag: Sofosbuvir

No Monopoly over Hepatitis C- SIPO

A long battle over the monopoly control of Hepatitis C medicine was concluded by China’s State Intellectual Property Office (SIPO). SIPO has cancelled the Patent claims for oral drug hepatitis C drug ‘sofosbuvir’, which was earlier granted to US pharmaceutical corporation Gilead Sciences.   This drug was an important medicine that was used for treatment of … Continue reading No Monopoly over Hepatitis C- SIPO

Read more »

Battle of the Brands: Gilead Sciences Inc. vs. Merck & Co. Inc

The legal dispute between the two pharmaceutical majors Gilead Sciences Inc. and Merck & Co. Inc. involving Hepatitis C drugs clearly indicates the high stakes involved when it comes to intellectual property. It all began in 2013, back in the day when Gilead Sciences Inc, filed for a New Drug application (NDA) with the FDA … Continue reading Battle of the Brands: Gilead Sciences Inc. vs. Merck & Co. Inc

Read more »